A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
about
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A phase 1 study combining the ...... b with and without irinotecan.
@en
A phase 1 study combining the HER3 antibody seribantumab
@nl
type
label
A phase 1 study combining the ...... b with and without irinotecan.
@en
A phase 1 study combining the HER3 antibody seribantumab
@nl
prefLabel
A phase 1 study combining the ...... b with and without irinotecan.
@en
A phase 1 study combining the HER3 antibody seribantumab
@nl
P2093
P2860
P1476
A phase 1 study combining the ...... b with and without irinotecan.
@en
P2093
Akos Czibere
Autumn J McRee
Bert H O'Neil
Gavin MacBeath
Geoffrey I Shapiro
James M Cleary
Jeffrey D Kearns
Rachel Nering
Sara M Tolaney
Sara Mathews
P2860
P2888
P356
10.1007/S10637-016-0399-7
P577
2016-11-16T00:00:00Z
P6179
1019747909